CHYHY
Chr. Hansen Holding A/S [CHYHY] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CHYHY Stock Summary
In the News
CHYHY Financial details
Company Rating
Strong Buy
Market Cap
10.31B
Income
226.96M
Revenue
1.33B
Book val./share
14.19
Cash/share
0.42
Dividend
0.27
Dividend %
1.45%
Employees
3.83K
Optionable
No
Shortable
Yes
Earnings
31 May 2023
P/E
58.46
Forward P/E
-
PEG
7.5
P/S
10.03
P/B
5.29
P/C
46.63
P/FCF
82.95
Quick Ratio
0.21
Current Ratio
1.67
Debt / Equity
0.52
LT Debt / Equity
0.49
-
-
EPS (TTM)
0.77
EPS next Y
-
EPS next Q
-
EPS this Y
300%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
29.62%
Revenue last 5Y
2.79%
Revenue Q/Q
5.15%
EPS Q/Q
309.09%
-
-
-
-
SMA20
-1.67%
SMA50
-2.02%
SMA100
-
Inst Own
0%
Inst Trans
0.1%
ROA
5%
ROE
9%
ROC
0.08%
Gross Margin
54%
Oper. Margin
26%
Profit Margin
17%
Payout
75%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
14.726-25.32
52W High
-21.66%
52W Low
+39.89%
RSI
48.98
Rel Volume
0.29
Avg Volume
25.23K
Volume
7.34K
Perf Week
0.69%
Perf Month
-4.09%
Perf Quarter
-
Perf Half Y
24.82%
-
-
-
-
Beta
0.306
-
-
Volatility
0.15%, 0.48%
Prev Close
0.85%
Price
19.585
Change
0.85%
CHYHY Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-08-31
| Metric | History | 2019-08-31 | 2020-08-31 | 2021-08-31 | 2022-08-31 | 2023-08-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 2.2 | 1.84 | 2.04 | 2.31 | 10.09 | |
| Net income per share | 0.47 | 0.46 | 0.38 | 0.43 | 1.72 | |
| Operating cash flow per share | 0.57 | 0.69 | 0.59 | 0.59 | 2.4 | |
| Free cash flow per share | 0.3 | 0.47 | 0.29 | 0.32 | 1.36 | |
| Cash per share | 0.17 | 0.17 | 0.08 | 0.06 | 0.42 | |
| Book value per share | 1.51 | 1.69 | 3.08 | 0.34 | 14.39 | |
| Tangible book value per share | -0.38 | -1.28 | -0.46 | -3.21 | 0.51 | |
| Share holders equity per share | 1.51 | 1.69 | 3.08 | 0.34 | 14.39 | |
| Interest debt per share | 1.58 | 2.72 | 1.85 | 1.85 | 7.7 | |
| Market cap | 10.11B | 12.68B | 10.31B | 7.7B | 2.01B | |
| Enterprise value | 10.84B | 14B | 11.21B | 8.58B | 2.94B | |
| P/E ratio | 40.4 | 51.75 | 51.89 | 34.2 | 8.85 | |
| Price to sales ratio | 8.71 | 13.07 | 9.57 | 6.32 | 1.51 | |
| POCF ratio | 33.85 | 34.77 | 33.17 | 24.93 | 6.34 | |
| PFCF ratio | 63.57 | 51.58 | 66.56 | 46.05 | 11.14 | |
| P/B Ratio | 12.68 | 14.2 | 6.34 | 42.56 | 1.06 | |
| PTB ratio | 12.68 | 14.2 | 6.34 | 42.56 | 1.06 | |
| EV to sales | 9.34 | 14.44 | 10.4 | 7.04 | 2.2 | |
| Enterprise value over EBITDA | 26.45 | 34.53 | 28.83 | 20.33 | 6.28 | |
| EV to operating cash flow | 36.31 | 38.41 | 36.06 | 27.78 | 9.28 | |
| EV to free cash flow | 68.19 | 56.97 | 72.36 | 51.32 | 16.31 | |
| Earnings yield | 0.02 | 0.02 | 0.02 | 0.03 | 0.11 | |
| Free cash flow yield | 0.02 | 0.02 | 0.02 | 0.02 | 0.09 | |
| Debt to equity | 1.03 | 1.59 | 0.59 | 5.33 | 0.52 | |
| Debt to assets | 0.4 | 0.5 | 0.31 | 0.29 | 0.29 | |
| Net debt to EBITDA | 1.79 | 3.27 | 2.31 | 2.09 | 1.99 | |
| Current ratio | 1.31 | 0.6 | 0.95 | 1.29 | 1.44 | |
| Interest coverage | 23.84 | 23.89 | 13.54 | 30.56 | 12.23 | |
| Income quality | 0.88 | 1.16 | 1.13 | 0.96 | 1.4 | |
| Dividend Yield | 0.02 | 0.01 | 0.01 | 0.02 | 0.06 | |
| Payout ratio | 0.9 | 0.51 | 0.58 | 0.51 | 0.55 | |
| Sales general and administrative to revenue | 0.06 | 0.05 | 0.07 | 0.07 | 0.06 | |
| Research and developement to revenue | 0.07 | 0.08 | 0.08 | 0.08 | 0.07 | |
| Intangibles to total assets | 0.49 | 0.55 | 0.6 | 0.57 | 0.53 | |
| Capex to operating cash flow | -0.47 | -0.33 | -0.5 | -0.46 | -0.43 | |
| Capex to revenue | -0.12 | -0.12 | -0.14 | -0.12 | -0.1 | |
| Capex to depreciation | -2.16 | -1.42 | -1.54 | -1.32 | -1.2 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0.01 | 0 | |
| Graham number | 4.02 | 4.2 | 5.11 | 1.81 | 23.58 | |
| ROIC | 0.16 | 0.11 | 0.08 | 0.2 | 0.09 | |
| Return on tangible assets | 0.24 | 0.19 | 0.16 | 0.16 | 0.14 | |
| Graham Net | -1.77 | -3.18 | -2.29 | -5.4 | -8.98 | |
| Working capital | 113.1M | -410.2M | -22.5M | 111.2M | 158.83M | |
| Tangible asset value | -201.2M | -677.8M | -243.2M | -1.69B | 66.29M | |
| Net current asset value | -786.6M | -1.35B | -1.06B | -2.64B | -1.01B | |
| Invested capital | 1.03 | 1.59 | 0.59 | 5.33 | 0.52 | |
| Average receivables | 107.8M | 194.7M | 200.5M | 224.62M | 239.06M | |
| Average payables | 125.35M | 116.65M | 116.65M | 132.3M | 121.98M | |
| Average inventory | 153.45M | 141.15M | 128.1M | 157.25M | 187.36M | |
| Days sales outstanding | 67.78 | 65.4 | 76.97 | 66.54 | 70.16 | |
| Days payables outstanding | 94.34 | 95.69 | 103.91 | 89.31 | 66.68 | |
| Days of inventory on hand | 114.26 | 115.65 | 105.33 | 121.73 | 116.13 | |
| Receivables turnover | 5.39 | 5.58 | 4.74 | 5.49 | 5.2 | |
| Payables turnover | 3.87 | 3.81 | 3.51 | 4.09 | 5.47 | |
| Inventory turnover | 3.19 | 3.16 | 3.47 | 3 | 3.14 | |
| ROE | 0.31 | 0.27 | 0.12 | 1.24 | 0.12 | |
| Capex per share | -0.26 | -0.23 | -0.3 | -0.27 | -1.03 |
Quarterly Fundamentals Overview
Last date of statement is 2023-08-31 for Q4
| Metric | History | 2022-08-31 | 2022-11-30 | 2023-02-28 | 2023-05-31 | 2023-08-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.63 | 0.59 | 0.63 | 0.64 | 2.63 | |
| Net income per share | 0.12 | 0.09 | 0.11 | 0.11 | 0.45 | |
| Operating cash flow per share | 0.23 | 0.06 | 0.12 | 0.2 | 0.85 | |
| Free cash flow per share | 0.1 | 0.03 | 0.06 | 0.13 | 0.46 | |
| Cash per share | 0.06 | 0.1 | 0.1 | -0.02 | 0.42 | |
| Book value per share | 0.35 | 3.34 | 3.35 | 3.54 | 14.19 | |
| Tangible book value per share | -3.27 | -0.24 | -0.11 | 0 | 0.5 | |
| Share holders equity per share | 0.35 | 3.34 | 3.35 | 3.54 | 14.19 | |
| Interest debt per share | 1.85 | 2.03 | 1.97 | 2.02 | 7.44 | |
| Market cap | 7.56B | 7.59B | 8.63B | 8.76B | 2.03B | |
| Enterprise value | 8.44B | 8.59B | 9.62B | 9.74B | 2.97B | |
| P/E ratio | 30.45 | 38.35 | 36.76 | 37.38 | 8.46 | |
| Price to sales ratio | 23.06 | 24.53 | 25.55 | 26.17 | 5.78 | |
| POCF ratio | 64.7 | 227.32 | 135.92 | 82.51 | 17.9 | |
| PFCF ratio | 144.06 | 468.67 | 252.37 | 128.11 | 33.06 | |
| P/B Ratio | 41.81 | 4.36 | 4.83 | 4.76 | 1.07 | |
| PTB ratio | 41.81 | 4.36 | 4.83 | 4.76 | 1.07 | |
| EV to sales | 25.75 | 27.76 | 28.47 | 29.1 | 8.43 | |
| Enterprise value over EBITDA | 98.64 | 116.4 | 100.17 | 109 | 23.19 | |
| EV to operating cash flow | 72.23 | 257.2 | 151.44 | 91.75 | 26.09 | |
| EV to free cash flow | 160.83 | 530.27 | 281.18 | 142.46 | 48.2 | |
| Earnings yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.03 | |
| Free cash flow yield | 0.01 | 0 | 0 | 0.01 | 0.03 | |
| Debt to equity | 5.33 | 0.6 | 0.58 | 0.57 | 0.52 | |
| Debt to assets | 0.29 | 0.32 | 0.31 | 0.31 | 0.29 | |
| Net debt to EBITDA | 10.29 | 13.52 | 10.26 | 10.98 | 7.28 | |
| Current ratio | 1.29 | 1.66 | 1.64 | 1.67 | 1.44 | |
| Interest coverage | -25.74 | 9.92 | 6.6 | 18.73 | 10.81 | |
| Income quality | 1.34 | 0.44 | 0.74 | 1.26 | 1.89 | |
| Dividend Yield | 0 | 0.02 | 0 | 0 | 0 | |
| Payout ratio | 0 | 2.52 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.07 | 0.06 | 0.06 | 0.06 | 0.06 | |
| Research and developement to revenue | 0.08 | 0.08 | 0.07 | 0.07 | 0.07 | |
| Intangibles to total assets | 0.57 | 0.57 | 0.55 | 0.54 | 0.53 | |
| Capex to operating cash flow | -0.55 | -0.51 | -0.46 | -0.36 | -0.46 | |
| Capex to revenue | -0.2 | -0.06 | -0.09 | -0.11 | -0.15 | |
| Capex to depreciation | -2.16 | -0.64 | -1.06 | -1.34 | -1.7 | |
| Stock based compensation to revenue | 0.02 | 0 | 0 | 0 | 0 | |
| Graham number | 0.97 | 2.67 | 2.88 | 2.99 | 11.98 | |
| ROIC | 0.06 | 0.02 | 0.02 | 0.02 | 0.03 | |
| Return on tangible assets | 0.04 | 0.03 | 0.04 | 0.04 | 0.04 | |
| Graham Net | -5.5 | -2.36 | -2.26 | -2.47 | -8.85 | |
| Working capital | 111.2M | 192.5M | 201.6M | 206.8M | 158.83M | |
| Tangible asset value | -1.69B | -122.9M | -60.4M | -1.8M | 66.29M | |
| Net current asset value | -2.64B | -1.06B | -1.03B | -1.04B | -1.01B | |
| Invested capital | 5.33 | 0.6 | 0.58 | 0.57 | 0.52 | |
| Average receivables | 111.02M | 217.92M | 225.13M | 230.93M | 240.74M | |
| Average payables | 120.45M | 120.5M | 111.15M | 107.65M | 106.48M | |
| Average inventory | 174M | 192.4M | 207.6M | 212.05M | 203.61M | |
| Days sales outstanding | 60.94 | 62.17 | 63 | 60.59 | 65.47 | |
| Days payables outstanding | 82.81 | 68.48 | 65.65 | 59.67 | 62.97 | |
| Days of inventory on hand | 112.88 | 128.88 | 121.73 | 125.27 | 109.68 | |
| Receivables turnover | 1.48 | 1.45 | 1.43 | 1.49 | 1.37 | |
| Payables turnover | 1.09 | 1.31 | 1.37 | 1.51 | 1.43 | |
| Inventory turnover | 0.8 | 0.7 | 0.74 | 0.72 | 0.82 | |
| ROE | 0.34 | 0.03 | 0.03 | 0.03 | 0.03 | |
| Capex per share | -0.12 | -0.03 | -0.05 | -0.07 | -0.39 |
CHYHY Frequently Asked Questions
What is Chr. Hansen Holding A/S stock symbol ?
Chr. Hansen Holding A/S is a DK stock and trading under the symbol CHYHY
What is Chr. Hansen Holding A/S stock quote today ?
Chr. Hansen Holding A/S stock price is $19.585 today.
Is Chr. Hansen Holding A/S stock public?
Yes, Chr. Hansen Holding A/S is a publicly traded company.
Company Profile
- Volume Average 25.23K
- Market Capitalization 10.31B
- Employee 3.83K
- CEO Mr. Mauricio Graber
- Headquarters Horsholm,DK
- IPO Date 2014-03-03
-
Website
https://www.chr-hansen.com 
Chr. Hansen Holding A/S, a bioscience company, develops natural ingredient solutions for the food, nutritional, pharmaceutical, and agricultural industries in Europe, the Middle East, Africa, North America, Latin America, and the Asia Pacific. It operates through Food Cultures & Enzymes, and Health & Nutrition segments. The Food Cultures & Enzymes segment produces and sells various cultures, enzymes, and probiotic products that determine the taste, flavor, texture, shelf life, nutritional value, and health benefits of various consumer products in the food industry, primarily in the dairy industry. The Health & Nutrition segment produces and sells products for the dietary supplement, over-the-counter pharmaceutical, infant formula, animal feed, and plant protection industries. It has a strategic collaboration with UPL Ltd. to develop and commercialize microbial-based bio solutions for sustainable agriculture. The company was founded in 1843 and is headquartered in Hørsholm, Denmark.
